DERMOL™ 200 SHOWER EMOLLIENT
Liquid Paraffin 2.5% w/w; Isopropyl Myristate 2.5% w/w; Benzalkonium Chloride 0.1% w/w; Chlorhexidine Dihydrochloride 0.1% w/w.
White, non-greasy cutaneous emulsion.
An antimicrobial shower emollient for the management of dry and pruritic skin conditions, especially eczema and dermatitis. Dermol 200 Shower Emollient is for direct application onto the skin and is suitable for use as a soap substitute.
For adults, children and the elderly: For application to the skin (eg after showering): Apply to the affected areas as required. Massage into the skin, until absorbed. For use as a soap substitute in the shower: As required, use the shower emollient instead of an ordinary shower gel or soap. Pat dry.
Do not use in cases of known sensitivity (especially generalised allergic reaction) to any of the ingredients (see sections 4.4 and 4.8).
Avoid contact with the eyes, especially when used on the face. Take care to avoid slipping in the shower or bath.
Local skin irritations (e.g. contact dermatitis) to any of the ingredients, in particular cetostearyl alcohol, are rare but possible in sensitive people. There are literature reports of chlorhexidine compounds inducing hypersensitivity, including anaphylactic shock. The prevalence of this is not known, but is likely to be very rare. Dermol 200 Shower Emollient should not be administered to anyone with a possible history of allergic reaction to a chlorhexidine compound (see sections 4.3 and 4.8).
Although the lotion has been specially formulated for use on dry or problem skin, in the unlikely event of a reaction discontinue treatment.
Local skin reactions
These reactions are very rare (<1/10,000, based on spontaneous reporting) and may be irritant or allergic in nature. Reactions have been observed occasionally when used excessively as a leave-on application in areas of folded skin such as the anogenital area.
Serious generalised allergic reactions
Very rarely, hypersensitivity including anaphylactic reaction (see sections 4.3 and 4.4) is possible (based on literature for chlorhexidine-containing products).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
Bacteria (especially Staphylococcus aureus
) are implicated in the pathogenesis of inflammatory dry skin conditions such as atopic eczema and dermatitis.
Dermol 200 Shower Emollient contains 5% of emollient oils in a non-greasy aqueous system which also contains the well-known and effective antiseptics benzalkonium chloride and chlorhexidine dihydrochloride. Its antimicrobial properties assist in overcoming infection, whether from Staph aureus
, the pathogen which often complicates eczema and associated pruritus, or secondary infection caused by scratching.
The emollients, liquid paraffin and isopropyl myristate, permit rehydration of dry skin by forming an occlusive barrier within the skin surface, thus reducing drying from evaporation of water that diffuses from the underlying layers.
Patients with dry skin conditions have a deficiency of the natural oils which assist in the retention of moisture.
A non-ionic emollient soap substitute such as Dermol 200 Shower Emollient, will cleanse the skin, helping to remove surface debris without removing the skin's natural oils.
The active ingredients are presented in an aqueous emulsion system and so are readily absorbed into the stratum corneum when the product is gently massaged over the areas of dry skin. The antiseptic ingredients are in intimate contact with the skin, and as they are in solution, their availability is optimal.
Cetostearyl Alcohol; Macrogol Cetostearyl Ether (cetomacrogol); Phenoxyethanol; Purified Water.
Plastic 200 ml bottle with a hooked overcap. This is supplied as an original pack (OP).
Tatmore Place, Gosmore
Hitchin, Herts SG4 7QR, UK.